Menu
Back to Journals » Drug Design, Development and Therapy » Volume 13
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Response to letter]
Authors Abe M, Tsushima K, Tatsumi K
Received 4 March 2019
Accepted for publication 4 March 2019
Published 14 May 2019 Volume 2019:13 Pages 1687—1688
Mitsuhiro Abe,1 Kenji Tsushima,1,2 Koichiro Tatsumi1
1Department of Respirology, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba city, Chiba 260-8670, Japan; 2Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Narita city, Chiba 286-8686, Japan
In our study, we observed that even in Severe Group of patients with interstitial pulmonary fibrosis (IPF), nintedanib administration suppressed the reduction in the forced vital capacity (FVC) (Figure 3).1 However, the frequency of side effects tended to be more (Table 2) and the prognosis was significantly worse in Severe Group than in Mild Group (Figure 5).
View the original paper by Orsatti and colleagues.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.